Results 171 to 180 of about 655,557 (182)

Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor

ACS Medicinal Chemistry Letters, 2020
Chunli Shen, Guanglong Sun, Chengde Wu
exaly  

Discovery of -(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor

European Journal of Medicinal Chemistry, 2017
Zhenquan Hu, Jing Liu, Cai-Hong Yun
exaly  

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton’s tyrosine kinase (BTK) inhibitor

Frontiers in Pharmacology, 2023
exaly  

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

New England Journal of Medicine, 2019
Martin S Weber, Xavier Montalban, Jerry S Wolinsky   +2 more
exaly  

Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines

European Journal of Medicinal Chemistry, 2019
Youcai Deng, Zhijin Fan, Bin Zhao
exaly  

The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma

International Journal of Cancer, 2018
Yuqin Song, Xiaogan Wang
exaly  

The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review

European Journal of Medicinal Chemistry, 2018
Chengyuan Liang, Suresh Thareja, Xiaodong Ren   +2 more
exaly  

A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation

Bioorganic and Medicinal Chemistry Letters, 2019
Yan Lou, Andreas Kuglstatter
exaly  

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Free

Blood, 2016
David J Gottlieb, Judith Trotman, Stephen Opat   +2 more
exaly  

Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function*

Journal of Biological Chemistry, 2016
William E Carson, Shalini Gautam, Li Ren
exaly